β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease

Molecular Genetics and Metabolism

Volumn 105, Issue 2, 2012, Pages 221-227

  Koeberl, Dwight D ^a   Li, Songtao ^a   Dai, Jian ^a   Thurberg, Beth L ^b   Bali, Deeksha ^a   Kishnani, Priya S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b GENZYME CORPORATION   (United States)

Author keywords

Acid alpha glucosidase; Acid maltase; Enzyme replacement therapy; Glycogen storage disease type II; Mannose 6 phosphate receptor; Pompe disease

Indexed keywords

CATION; CLENBUTEROL; GLYCOGEN; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; SALBUTAMOL; SOMATOMEDIN B RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CEREBELLUM; CEREBELLUM CORTEX; DRUG DOSE REDUCTION; DRUG EFFICACY; ENZYME REPLACEMENT; GLYCOGEN ANALYSIS; GLYCOGEN STORAGE DISEASE TYPE 2; HISTOPATHOLOGY; LOW DRUG DOSE; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKELETAL MUSCLE;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; ALPHA-GLUCOSIDASES; ANIMALS; CLENBUTEROL; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; ENZYME REPLACEMENT THERAPY; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; MICE; RECEPTOR, IGF TYPE 2;

MURINAE; MUS;

EID: 84856100399     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2011.11.005     Document Type: Article

References (34)

1. Raben N., Jatkar T., Lee A., Lu N., Dwivedi S., Nagaraju K., Plotz P. Glycogen stored in skeletal but not in cardiac muscle in acid alpha-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme. Mol. Ther. 2002, 6:601-608.
2. Raben N., Danon M., Gilbert A.L., Dwivedi S., Collins B., Thurberg B.L., Mattaliano R.J., Nagaraju K., Plotz P.H. Enzyme replacement therapy in the mouse model of Pompe disease. Mol. Genet. Metab. 2003, 80:159-169.
3. Cardone M., Porto C., Tarallo A., Vicinanza M., Rossi B., Polishchuk E., Donaudy F., Andria G., De Matteis M.A., Parenti G. Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts. Pathogenetics 2008, 1:6.
4. Mcvie-Wylie A.J., Lee K.L., Qiu H., Jin X., Do H., Gotschall R., Thurberg B.L., Rogers C., Raben N., O'callaghan M., Canfield W., Andrews L., Mcpherson J.M., Mattaliano R.J. Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease. Mol. Genet. Metab. 2008, 94:448-455.
5. Zhu Y., Jiang J.L., Gumlaw N.K., Zhang J., Bercury S.D., Ziegler R.J., Lee K., Kudo M., Canfield W.M., Edmunds T., Jiang C., Mattaliano R.J., Cheng S.H. Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Mol. Ther. 2009, 17:954-963.
6. Nicolino M., Byrne B., Wraith J.E., Leslie N., Mandel H., Freyer D.R., Arnold G.L., Pivnick E.K., Ottinger C.J., Robinson P.H., Loo J.C., Smitka M., Jardine P., Tato L., Chabrol B., Mccandless S., Kimura S., Mehta L., Bali D., Skrinar A., Morgan C., Rangachari L., Corzo D., Kishnani P.S. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet. Med. 2009, 11:210-219.
7. Jones H.N., Muller C.W., Lin M., Banugaria S.G., Case L.E., Li J.S., O'grady G., Heller J.H., Kishnani P.S. Oropharyngeal dysphagia in infants and children with infantile Pompe disease. Dysphagia 2010, 25:277-283.
8. Yanovitch T.L., Banugaria S.G., Proia A.D., Kishnani P.S. Clinical and histologic ocular findings in pompe disease. J. Pediatr. Ophthalmol. Strabismus 2010, 47:34-40.
9. Kobayashi H., Shimada Y., Ikegami M., Kawai T., Sakurai K., Urashima T., Ijima M., Fujiwara M., Kaneshiro E., Ohashi T., Eto Y., Ishigaki K., Osawa M., Kyosen S.O., Ida H. Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case. Mol. Genet. Metab. 2010, 100:14-19.
10. Strothotte S., Strigl-Pill N., Grunert B., Kornblum C., Eger K., Wessig C., Deschauer M., Breunig F., Glocker F.X., Vielhaber S., Brejova A., Hilz M., Reiners K., Muller-Felber W., Mengel E., Spranger M., Schoser B. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J. Neurol. 2010, 257:91-97.
11. Thurberg B.L., Lynch Maloney C., Vaccaro C., Afonso K., Tsai A.C., Bossen E., Kishnani P.S., O'callaghan M. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab. Invest. 2006, 86:1208-1220.
12. Raben N., Fukuda T., Gilbert A.L., De Jong D., Thurberg B.L., Mattaliano R.J., Meikle P., Hopwood J.J., Nagashima K., Nagaraju K., Plotz P.H. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Mol. Ther. 2005, 11:48-56.
13. Koeberl D.D., Luo X., Sun B., Mcvie-Wylie A., Dai J., Li S., Banugaria S.G., Chen Y.T., Bali D.S. Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle. Mol. Genet. Metab. 2011, 103:107-112.
14. Sun B., Li S., Bird A., Yi H., Kemper A., Thurberg B.L., Koeberl D.D. Antibody formation and mannose-6-phosphate receptor expression impact the efficacy of muscle-specific transgene expression in murine Pompe disease. J. Gene Med. 2010, 12:881-891.
15. Raben N., Lu N., Nagaraju K., Rivera Y., Lee A., Yan B., Byrne B., Meikle P.J., Umapathysivam K., Hopwood J.J., Plotz P.H. Conditional tissue-specific expression of acid alpha-glucosidase (GAA) gene in the GAA knockout mice: implications for therapy. Human Mol. Genet. 2001, 10:2039-2047.
16. Kishnani P.S., Corzo D., Nicolino M., Byrne B., Mandel H., Hwu W.L., Leslie N., Levine J., Spencer C., Mcdonald M., Li J., Dumontier J., Halberthal M., Chien Y.H., Hopkin R., Vijayaraghavan S., Gruskin D., Bartholomew D., Van Der P.A., Clancy J.P., Parini R., Morin G., Beck M., De La Gastine G.S., Jokic M., Thurberg B., Richards S., Bali D., Davison M., Worden M.A., Chen Y.T., Wraith J.E. Recombinant human acid {alpha}-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007, 68:99-109.
17. Matsumoto T., Akutsu S., Wakana N., Morito M., Shimada A., Yamane A. The expressions of insulin-like growth factors, their receptors, and binding proteins are related to the mechanism regulating masseter muscle mass in the rat. Arch. Oral Biol. 2006, 51:603-611.
18. Lynch G.S., Ryall J.G. Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. Physiol. Rev. 2008, 88:729-767.
19. Sandri M. Signaling in muscle atrophy and hypertrophy. Physiology (Bethesda) 2008, 23:160-170.
20. Mounier R., Cavalie H., Lac G., Clottes E. Molecular impact of clenbuterol and isometric strength training on rat EDL muscles. Pflugers Arch. 2007, 453:497-507.
21. Maclennan P.A., Edwards R.H. Effects of clenbuterol and propranolol on muscle mass. Evidence that clenbuterol stimulates muscle beta-adrenoceptors to induce hypertrophy. Biochem. J. 1989, 264:573-579.
22. Awede B.L., Thissen J.P., Lebacq J. Role of IGF-I and IGFBPs in the changes of mass and phenotype induced in rat soleus muscle by clenbuterol. Am. J. Physiol. Endocrinol. Metab. 2002, 282:E31-E37.
23. Plant D.R., Kearns C.F., Mckeever K.H., Lynch G.S. Therapeutic clenbuterol treatment does not alter Ca2+ sensitivity of permeabilized fast muscle fibres from exercise trained or untrained horses. J. Muscle Res. Cell Motil. 2003, 24:471-476.
24. Oya Y., Morita H., Ogawa M., Nonaka I., Tsujino S., Kawai M. Adult form of acid maltase deficiency presenting with pattern of muscle weakness resembling facioscapulohumeral dystrophy. Rinsho Shinkeigaku 2001, 41:390-396.
25. Angelini C., Menegazzo E., Marcon M., Marsala S.Z., Roni V. An open trial of albuterol and branched chain aminoacids in adult acid maltase deficiency. Neurology 1998, 50:A369-A369.
26. Grubb J.H., Vogler C., Sly W.S. New strategies for enzyme replacement therapy for lysosomal storage diseases. Rejuvenation Res. 2010, 13:229-236.
27. Blanz J., Stroobants S., Lullmann-Rauch R., Morelle W., Ludemann M., D'hooge R., Reuterwall H., Michalski J.C., Fogh J., Andersson C., Saftig P. Reversal of peripheral and central neural storage and ataxia after recombinant enzyme replacement therapy in alpha-mannosidosis mice. Hum. Mol. Genet. 2008, 17:3437-3445.
28. Grubb J.H., Vogler C., Levy B., Galvin N., Tan Y., Sly W.S. Chemically modified beta-glucuronidase crosses blood-brain barrier and clears neuronal storage in murine mucopolysaccharidosis VII. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:2616-2621.
29. Daly T.M., Okuyama T., Vogler C., Haskins M.E., Muzyczka N., Sands M.S. Neonatal intramuscular injection with recombinant adeno-associated virus results in prolonged beta-glucuronidase expression in situ and correction of liver pathology in mucopolysaccharidosis type VII mice. Hum. Gene Ther. 1999, 10:85-94.
30. Daly T.M., Ohlemiller K.K., Roberts M.S., Vogler C.A., Sands M.S. Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer. Gene Ther. 2001, 8:1291-1298.
31. Polito V.A., Cosma M.P. IDS crossing of the blood-brain barrier corrects CNS defects in MPSII mice. Am. J. Hum. Genet. 2009, 85:296-301.
32. Mccarty D.M., Dirosario J., Gulaid K., Muenzer J., Fu H. Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice. Gene Ther. 2009, 16:1340-1352.
33. Wraith J.E., Scarpa M., Beck M., Bodamer O.A., De Meirleir L., Guffon N., Meldgaard Lund A., Malm G., Van Der Ploeg A.T., Zeman J. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur. J. Pediatr. 2008, 167:267-277.
34. Matthes F., Wölte P., Böchenhoff A., Hüwel S., Schulz M., Hyden P., Fogh J., Gieselmann V., Galla H.J., Matzner U. Transport of arylsulfatase A across the blood-brain barrier in vitro. J. Biol. Chem. 2011, 286:17487-17494.